Skip to main content

Waddill William D.'s Form 4 filing

Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 23, 2025

Accession no.
0001553338-25-000005
Filed
Dec 23, 2025
Trade date
Dec 19, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $566.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Waddill William D.CIK 0001553338Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 19, 2025Common StockSSaleDisposed−2,416$66.66−$161,050.5662,514Direct
Dec 19, 2025Common StockSSaleDisposed−5,451$68.01−$370,722.5157,063Direct
Dec 19, 2025Common StockSSaleDisposed−500$68.53−$34,26556,563Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)